Efficacy of a once-monthly pill containing ibandronate and cholecalciferol on the levels of 25-hydroxyvytamin D and bone markers in postmenopausal women with osteoporosis
- Author(s)
- In-Jin Cho; Ho-Yeon Chung; Sung-Woon Kim; Jae-Won Lee; Tae-Won Lee; Hye-Soon Kim; Sin-Gon Kim; Han Seok Choi; Sung-Hee Choi; Chan Soo Shin; Ki-Won Oh; Yong-Ki Min; Jung-Min Koh; Yumie Rhee; Dong-Won Byun; Yoon-Sok Chung; Jeong Hyun Park; Dong Jin Chung; Minho Shong; Eun-Gyoung Hong; Chang Beom Lee; Ki Hyun Baek; Moo-Il Kang
- Keimyung Author(s)
- Kim, Hye Soon
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Endocrinology and Metabolism
- Issued Date
- 2015
- Volume
- 30
- Issue
- 3
- Keyword
- Ibandronate; Cholecalciferol; 25-hydroxyvitamin D; Bone markers
- Abstract
- Background: The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis.
Methods: This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: the IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH)D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period. Results: After 16 weeks of treatment, the mean serum levels of 25(OH)D significantly increased from 21.0 to 25.3 ng/mL in the
IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant
increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and
C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in
subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN
treatment.
Conclusion: The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful
for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination
effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week
treatment period.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.